Reckitt Benckiser Group plc announced that Harry Kirsch, a Non-Executive Director, has been appointed to the Board of Galderma, effective April 22, 2026. This appointment is in accordance with Listing Rule 9.6.14 of the FCA's Listing Rules.
Reckitt Benckiser Group plc ('Reckitt') announces that Harry Kirsch, a Non-Executive Director for Reckitt, has been appointed as a Director on the Board of Galderma (SIX: GALD), from 22 April 2026.
This notification is made in accordance with Listing Rule 9.6.14 of the FCA's Listing Rules.
CONTACT DETAILS:
Contacts
Nick Ashworth +44 (0) 7408 812350
SVP Investor Relations
Catheryn O'Rourke +44 (0) 1753 217 800
General Counsel & Company Secretary
About Reckitt:
We make the products people trust to care for the ones they love. We are home to some of the world's best-loved consumer health and hygiene brands, including Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen, Strepsils, Vanish and Veet. Consumers are at the heart of everything we do. By creating innovative, science-backed solutions, we support people every day to live healthier lives.
Reckitt exists to protect, heal and nurture in the pursuit of a cleaner, healthier world. This commitment goes beyond the products we make. Through our actions, we expand access to healthcare, education and economic opportunities. We support the planet by reducing waste, conserving resources and driving sustainable innovation.
We believe good health starts at home. With every action we take, we strive to make our consumers' lives easier, cleaner and healthier, to strengthen communities and to create a more sustainable future.
*Reckitt is the trading name of the Reckitt Benckiser group of companies
Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may contain inaccuracies, outdated information, or subjective interpretations. This content is intended for general informational purposes only and should not be considered professional advice or factual confirmation.
We encourage you to independently verify any information provided, especially if it will be relied upon for making decisions or taking action. Any reliance you place on this material is strictly at your own risk. The AI system that produced this content cannot assess the specifics of individual circumstances, and results may vary based on context and individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.